EVAX
Evaxion AS
NASDAQ · Healthcare · Biotechnology · DK
$3.33
+17.67%Year over year
Reported trailing growth
- Revenue
- +135.9%
- EBITDA
- +25.5%
- EBIT
- +37.8%
- EPS
- +42.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -94.4%
- EBITDA
- +75.4%
- EPS
- +80.6%
Three-year CAGR
- Revenue
- +915.5%
- EBITDA
- +27.2%
- EBIT
- +37.3%
- Net income
- +27.1%
- EPS
- +87.7%
- Free cash flow
- +48.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026